This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Opiant Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO Opiant Pharmaceuticals is Roger Crystal, benoemd in Sep2009, heeft een ambtstermijn van 13.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.48M, bestaande uit 42.9% salaris en 57.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.64% van de aandelen van het bedrijf, ter waarde $ 695.26K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.5 jaar en 6.8 jaar.

Belangrijke informatie

Roger Crystal

Algemeen directeur

US$1.5m

Totale compensatie

Percentage CEO-salaris	42.9%
Dienstverband CEO	13.5yrs
Eigendom CEO	0.6%
Management gemiddelde ambtstermijn	5.5yrs
Gemiddelde ambtstermijn bestuur	6.8yrs

Recente managementupdates

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

Analyse CEO-vergoeding

Hoe is Roger Crystal's beloning veranderd ten opzichte van Opiant Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$20m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$1m	US$635k	US$3m
Sep 30 2021	n/a	n/a	US$2m
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$1m	US$610k	-US$2m
Sep 30 2020	n/a	n/a	-US$108k
Jun 30 2020	n/a	n/a	US$10m
Mar 31 2020	n/a	n/a	US$12m
Dec 31 2019	US$1m	US$592k	US$12m
Sep 30 2019	n/a	n/a	US$988k
Jun 30 2019	n/a	n/a	-US$11m
Mar 31 2019	n/a	n/a	-US$14m
Dec 31 2018	US$865k	US$574k	-US$21m
Sep 30 2018	n/a	n/a	-US$2m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	n/a	n/a	US$3m
Oct 31 2017	n/a	n/a	US$2m
Jul 31 2017	US$1m	US$568k	US$7m
Apr 30 2017	n/a	n/a	US$6m
Jan 31 2017	n/a	n/a	US$9m
Oct 31 2016	n/a	n/a	US$3m
Jul 31 2016	US$5m	US$616k	-US$8m

Compensatie versus markt: De totale vergoeding ($USD 1.48M ) Roger } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 650.00K ).

Compensatie versus inkomsten: De vergoeding van Roger is gestegen terwijl het bedrijf verliesgevend is.

CEO

Roger Crystal (46 yo)

13.5yrs

Tenure

US$1,477,846

Compensatie

Dr. Roger Crystal, M.D., has been an Independent Director of Mind Medicine (MindMed) Inc. since August 11, 2022. Dr. Crystal has been the Chief Executive Officer of Opiant Pharmaceuticals, Inc. since Septe...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Roger Crystal	President	13.5yrs	US$1.48m	0.64% $ 695.3k
David O'Toole	Chief Financial Officer	5.5yrs	US$786.67k	0.43% $ 464.9k
Phillip Skolnick	Chief Scientific Officer	6.1yrs	US$800.11k	0.19% $ 202.6k
Ben Atkins	Vice President of Communications & Investor Relations	no data	geen gegevens	geen gegevens
Brian Gorman	EVP Corporate Development & General Counsel	2.6yrs	geen gegevens	0.34% $ 369.9k
Mark Ellison	Chief Development Officer	no data	geen gegevens	0.36% $ 387.2k
Matthew Ruth	Chief Commercial Officer	1.7yrs	geen gegevens	0.13% $ 137.7k

5.5yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van OPNT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Roger Crystal	President	13.5yrs	US$1.48m	0.64% $ 695.3k
Michael Sinclair	Independent Director	12.3yrs	US$42.70k	1.14% $ 1.2m
Thomas Thomas	Independent Director	6.3yrs	US$113.70k	0.20% $ 214.2k
Craig Collard	Independent Chairman	4.4yrs	US$137.20k	1.02% $ 1.1m
Thomas Kosten	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Ann MacDougall	Independent Director	6.8yrs	US$109.70k	0.50% $ 540.6k
Sharon Walsh	Chairwoman of Medical Advisory Board	no data	geen gegevens	geen gegevens
Sandra Comer	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Marc Potenza	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Gabrielle Silver	Independent Director	6.8yrs	US$103.70k	0.41% $ 440.7k
Stephanie O'Malley	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Wim van den Brink	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens

6.8yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van OPNT wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.8 jaar).

This company has been acquired

Opiant Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

President recently sold US$102k worth of stock

Insufficient new directors

Independent Director recently sold US$275k worth of stock

Independent Chairman recently bought US$368k worth of stock

Insufficient new directors

Opiant Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Recent updates

Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose

President recently sold US$102k worth of stock

Consensus revenue estimates increase by 15%

Price target decreased to US$21.50

Opiant Pharmaceuticals, Inc. Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose

Consensus revenue estimates fall by 45%

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Insufficient new directors

Indivior PLC (LSE:INDV) entered into a definitive agreement to acquire Opiant Pharmaceuticals, Inc. (NasdaqCM:OPNT) for approximately $110 million.

Opiant Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Opiant Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder

Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering Opnt004 for the Treatment of Cannabinoid Hyperemesis Syndrome

Consensus revenue estimates fall by 13%

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Opiant Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Opiant Pharmaceuticals, Inc. announced that it expects to receive $2.1 million in funding from AptarGroup, Inc., Valois SAS

Independent Director recently sold US$275k worth of stock

Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

Independent Chairman recently bought US$368k worth of stock

Consensus EPS estimates fall by 47%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Opiant Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 10, 2022

Opiant Pharmaceuticals, Inc. Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone

Insufficient new directors

Opiant Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Investor sentiment improved over the past week

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment deteriorated over the past week

President recently sold US$52k worth of stock

Opiant Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Trial of Opnt002

Investor sentiment deteriorated over the past week

Insufficient new directors

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Investor sentiment deteriorated over the past week

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS US$0.77 (vs US$0.17 in 3Q 2020)

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Independent Chairman recently bought US$174k worth of stock

Independent Director exercised options and sold US$1.6m worth of stock

Second quarter 2021 earnings released: EPS US$0.39 (vs US$0.051 loss in 2Q 2020)

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Consensus revenue estimates increase to US$37.0m

Opiant Pharmaceuticals, Inc.(NasdaqCM:OPNT) dropped from Russell 3000E Value Index

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

First quarter 2021 earnings released: US$0.66 loss per share (vs US$0.40 loss in 1Q 2020)

Opiant Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2021

Independent Director exercised options to buy US$101k worth of stock.

Analysts update estimates

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Full year 2020 earnings released: US$0.44 loss per share (vs US$2.89 profit in FY 2019)

Revenue and earnings beat expectations

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 04, 2021

Independent Director exercised options to buy US$97k worth of stock.

Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose

New 90-day high: US$12.96

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharmaceuticals, Inc. Appoints Craig A. Collard to the Compensation Committee of the Board

New 90-day high: US$9.29

Opiant Pharmaceuticals Announces Additional $3.5 Million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Opiant Pharmaceuticals receives $50M in convertible debt financing

Opiant Pharmaceuticals Announces Appointment of Craig A. Collard as Chairman to Its Board of Directors